Xencor (XNCR) Stock Forecast, Price & News

12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Xencor in the last year. There are currently 11 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" XNCR shares.
View XNCR analyst ratings or view top-rated stocks.

12 equities research analysts have issued 1 year target prices for Xencor's stock. Their XNCR share price forecasts range from $36.00 to $59.00. On average, they anticipate the company's share price to reach $44.20 in the next year. This suggests a possible upside of 119.5% from the stock's current price.
View analysts price targets for XNCR or view top-rated stocks among Wall Street analysts.

Xencor's stock was trading at $26.04 on January 1st, 2023. Since then, XNCR shares have decreased by 22.7% and is now trading at $20.14.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Monday, November 6th 2023.
View our XNCR earnings forecast.

Xencor, Inc. (NASDAQ:XNCR) released its quarterly earnings results on Thursday, August, 3rd. The biopharmaceutical company reported ($0.37) EPS for the quarter, beating the consensus estimate of ($0.91) by $0.54. The biopharmaceutical company had revenue of $45.52 million for the quarter, compared to analysts' expectations of $26.25 million. Xencor had a negative trailing twelve-month return on equity of 18.14% and a negative net margin of 112.46%. The firm's revenue for the quarter was up 50.9% on a year-over-year basis. During the same quarter in the previous year, the company posted ($0.57) EPS.

ETFs with the largest weight of Xencor (NASDAQ:XNCR) stock in their portfolio include Invesco Biotechnology & Genome ETF (PBE), Invesco S&P SmallCap Health Care ETF (PSCH) and iShares Genomics Immunology and Healthcare ETF (IDNA).ALPS Medical Breakthroughs ETF (SBIO).

6 employees have rated Xencor Chief Executive Officer Bassil I. Dahiyat on Glassdoor.com. Bassil I. Dahiyat has an approval rating of 81% among the company's employees.

Based on aggregate information from My MarketBeat watchlists, some companies that other Xencor investors own include Intelsat (I), Bank of America (BAC), Apollo Global Management (APO), Cypress Semiconductor (CY), NVIDIA (NVDA), AbbVie (ABBV), Exelixis (EXEL), Intel (INTC), AMC Entertainment (AMC) and Ciena (CIEN).

Xencor trades on the NASDAQ under the ticker symbol "XNCR."

Xencor's stock is owned by many different institutional and retail investors. Top institutional shareholders include BlackRock Inc. (16.75%), State Street Corp (5.12%), Dimensional Fund Advisors LP (2.60%), Geode Capital Management LLC (2.00%), Northern Trust Corp (1.23%) and Candriam S.C.A. (1.08%). Insiders that own company stock include Allen Yang, Bassil I Dahiyat, Bassil I Dahiyat, Celia Eckert and John J Kuch.
View institutional ownership trends.

Shares of XNCR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of XNCR stock can currently be purchased for approximately $20.14.

Xencor (NASDAQ:XNCR) has a market capitalization of $1.22 billion and generates $164.58 million in revenue each year. The biopharmaceutical company earns $-55,180,000.00 in net income (profit) each year or ($2.14) on an earnings per share basis.

The company employs 281 workers across the globe.

Xencor's mailing address is 111 WEST LEMON AVENUE, MONROVIA CA, 91016. The official website for the company is www.xencor.com. The biopharmaceutical company can be reached via phone at (626) 305-5900, via email at investors@xencor.com, or via fax at 626-305-0350.